California
Biotech Insights

Biotech Market Update

Artiva raises $300M, Perfuse acquired by Bayer

May 12, 2026

Recent Funding: Artiva Biotherapeutics (SD) Reports 71% Response Rate in Rheumatoid Arthritis Trial and Raises $300 Million Artiva’s off-the-shelf NK cell therapy AlloNK plus rituximab achieved a 71% ACR50 response (meaningful symptom improvement) in refractory rheumatoid arthritis patients at six months—dramatically outperforming the 11-19% response rate seen with current therapies in this difficult-to-treat population of […]

Biotech Market Update

Profluent partners with Lilly in $2.25B deal, Candid acquires UCB, Protagonist $475M payout

May 5, 2026

M&A, Deals, Partnerships: Protagonist Therapeutics (SF) Opts for $475 Million Payout Over U.S. Profit Split with Takeda Protagonist is cashing out its U.S. co-promotion rights for rusfertide — a drug for a rare blood disorder called polycythemia vera — taking $200 million now and another $275 million if the FDA approves the drug, expected later […]

Biotech Leader Spotlight

Leigh Hsu

Cofounder & CEO of Atticus Pharma

April 30, 2026

Leigh Hsu is a biotechnology executive with 25 years’ experience in the biopharma industry. Leigh is the Co-founder and Chief Executive Officer of Atticus Pharma, a therapeutics company developing drugs for immunodermatology and associated diseases utilizing their proprietary topical delivery system. Their two initial programs are for the treatment of cutaneous lupus lesions and androgenic alopecia. Previously he served as SVP of Business Development with CARsgen for seven years, and prior to that, he was with Lpath for six years as VP of Corporate Development & Strategy. Dr. Hsu received his PhD in molecular pathology from UC San Diego and an MBA from UC Irvine.

Biotech Market Update

Ray raises $125M Series B, Soleno sells Neurocrine for $2.9B, Kyverna reports CAR-T breakthrough

April 28, 2026

Recent Funding: Ray Therapeutics (SF) Raises $125 Million to Advance Gene Therapy for Vision Loss Ray Therapeutics closed an oversubscribed Series B round led by Janus Henderson Investors to fund its lead gene therapy RTx-015, which aims to restore vision in patients with retinitis pigmentosa — a genetic disease that progressively destroys the cells in […]

Biotech Market Update

Rev Med prices $2B public raise, Terremoto raises $108M Series B, Kailera raises record $625M IPO

April 21, 2026

Recent Funding: Neomorph (SD) Closes $100M Series B Led by Deerfield to Advance Molecular Glue Degrader Platform and NEO-811 Kidney Cancer Trial Neomorph closed $100 million Series B led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. Proceeds will […]

Biotech Market Update

Sidewinder raises $137M Series B, Gilead acquires Tubulis, Biotech VCs embrace risk again

April 14, 2026

Recent Funding: Sidewinder Therapeutics (SD) Raises $137M Series B to Develop Bispecific ADCs with Reduced Toxicity Sidewinder Therapeutics (7 employees, co-founded by Harvard scientist Ryan Corcoran and CEO Eric Murphy) raised $137 million Series B ($162 million total raised) led by OrbiMed, with Frazier Life Sciences, Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, […]

California Biotech Insights

California
Biotech Insights